ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2017
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 315 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
315 citing papers in PubMed, 4 syntheses or guidelines pooled it, 593 citations in OpenAlex.
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Prevalence of mild cognitive impairment in community-dwelling Chinese populations aged over 55 years: a meta-analysis and systematic review.BMC geriatrics · 2021Pooled it
- Apolipoprotein E Genotype Moderation of the Association Between Physical Activity and Brain Health. A Systematic Review and Meta-Analysis.Frontiers in aging neuroscience · 2021Pooled it
- Alzheimer's blood-based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- A Randomized Clinical Trial Reveals Effects of Mindfulness and Slow Breathing on Plasma Amyloid Beta Levels.Psychophysiology · 2025Trial
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.The Lancet. Neurology · 2025Trial
- Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity.JAMA network open · 2025Trial
- Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2024Trial
- Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial.Alzheimer's research & therapy · 2023Trial
- Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.Alzheimer's research & therapy · 2022Trial
- Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults.The journal of prevention of Alzheimer's disease · 2021Trial
- Longitudinal associations of rapid eye movement (REM) sleep and slow-wave sleep with plasma Alzheimer's disease biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Use of high-affinity scFv antibody NUsc1 for isolation and sensitive detection of Alzheimer's-associated amyloid beta oligomers.The Journal of biological chemistry · 2026Article
- Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity.Annals of neurology · 2026Article
- Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer's disease.Aging clinical and experimental research · 2026Article
- Establishing a Diagnostic Model Based on Plasma CDR1as and Alpha-Synuclein for Mild Cognitive Impairment in Type 2 Diabetes.Molecular neurobiology · 2026Article
- Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer's disease in individuals with subjective cognitive decline: 5-year follow-up of the FACEHBI cohort.The journal of prevention of Alzheimer's disease · 2026Article
- Multivariate patterns of plasma biomarkers predict region-specific Alzheimer's pathology and cognitive decline across independent cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
255 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2017
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
introductionCerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid-binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition.
methodsWe adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma.
resultsAβ isoforms have a half-life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid-positive participants were observed. DISCUSSION: Blood plasma Aβ42 shows similar amyloid-associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood-brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.